

JÃ¼rgen GÃ¼tz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1677803/publications.pdf>

Version: 2024-02-01

211
papers

22,077
citations

8755

75
h-index

9860

141
g-index

225
all docs

225
docs citations

225
times ranked

21558
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptional signature in microglia isolated from an Alzheimer's disease mouse model treated with scanning ultrasound. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	7.1	7
2	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.8	5
3	Exosomal and vesicle-free tau seeds propagation and convergence in endolysosomal permeabilization. <i>FEBS Journal</i> , 2022, 289, 6891-6907.	4.7	24
4	Claudin-5 binder enhances focused ultrasound-mediated opening in an <i>in vitro</i> blood-brain barrier model. <i>Theranostics</i> , 2022, 12, 1952-1970.	10.0	18
5	Ultrasound-Mediated Bioeffects in Senescent Mice and Alzheimer's Mouse Models. <i>Brain Sciences</i> , 2022, 12, 775.	2.3	3
6	Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice. <i>Acta Neuropathologica Communications</i> , 2021, 9, 42.	5.2	14
7	A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 76.	6.2	53
8	De novo proteomic methods for examining the molecular mechanisms underpinning long-term memory. <i>Brain Research Bulletin</i> , 2021, 169, 94-103.	3.0	13
9	Low-intensity ultrasound restores long-term potentiation and memory in senescent mice through pleiotropic mechanisms including NMDAR signaling. <i>Molecular Psychiatry</i> , 2021, 26, 6975-6991.	7.9	32
10	PINK1 and parkin shape the organism-wide distribution of a deleterious mitochondrial genome. <i>Cell Reports</i> , 2021, 35, 109203.	6.4	25
11	Altered ribosomal function and protein synthesis caused by tau. <i>Acta Neuropathologica Communications</i> , 2021, 9, 110.	5.2	27
12	Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer's Disease. <i>Pharmaceutics</i> , 2021, 13, 1002.	4.5	4
13	Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol. <i>Acta Neuropathologica</i> , 2021, 141, 235-256.	7.7	66
14	Super-resolution microscopy: a closer look at synaptic dysfunction in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2021, 22, 723-740.	10.2	33
15	Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies. <i>Journal of Neuroendocrinology</i> , 2020, 32, e12796.	2.6	22
16	The blood-brain barrier: Physiology and strategies for drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2020, 165-166, 1-14.	13.7	292
17	Fyn Kinase Controls Tau Aggregation <i>In Vivo</i> . <i>Cell Reports</i> , 2020, 32, 108045.	6.4	46
18	Role for caveolin-mediated transcytosis in facilitating transport of large cargoes into the brain via ultrasound. <i>Journal of Controlled Release</i> , 2020, 327, 667-675.	9.9	41

#	ARTICLE	IF	CITATIONS
19	PTEN activation contributes to neuronal and synaptic engulfment by microglia in tauopathy. <i>Acta Neuropathologica</i> , 2020, 140, 7-24.	7.7	24
20	Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery. <i>Stem Cell Reports</i> , 2020, 14, 924-939.	4.8	63
21	Cell-specific non-canonical amino acid labelling identifies changes in the de novo proteome during memory formation. <i>ELife</i> , 2020, 9, .	6.0	30
22	Scanning ultrasound in the absence of blood-brain barrier opening is not sufficient to clear Î²-amyloid plaques in the APP23 mouse model of Alzheimer's disease. <i>Brain Research Bulletin</i> , 2019, 153, 8-14.	3.0	26
23	Tauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1139-1151.	6.4	51
24	Repeated ultrasound treatment of tau transgenic mice clears neuronal tau by autophagy and improves behavioral functions. <i>Theranostics</i> , 2019, 9, 3754-3767.	10.0	82
25	Ultrasound-mediated blood-brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody. <i>Scientific Reports</i> , 2019, 9, 9255.	3.3	56
26	Decreased synthesis of ribosomal proteins in tauopathy revealed by non-Îµ-canonical amino acid labelling. <i>EMBO Journal</i> , 2019, 38, e101174.	7.8	84
27	The search for improved animal models of Alzheimer's disease and novel strategies for therapeutic intervention. <i>Future Medicinal Chemistry</i> , 2019, 11, 1853-1857.	2.3	7
28	Molecular Pathogenesis of the Tauopathies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 239-261.	22.4	161
29	Disease-Îµ-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. <i>EMBO Journal</i> , 2019, 38, .	7.8	161
30	Experimental Models of Tauopathy-Îµ From Mechanisms to Therapies. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 381-391.	1.6	16
31	Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines. <i>ELife</i> , 2019, 8, .	6.0	38
32	A Novel Antibody Targeting Tau Phosphorylated at Serine 235 Detects Neurofibrillary Tangles. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 899-905.	2.6	14
33	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	7.6	114
34	Amyloid-Î² and Tau in Alzheimer-Îµ's Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S517-S527.	2.6	42
35	Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo?. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 1151-1162.	5.4	57
36	Amyloid-Î² and tau complexity -Îµ towards improved biomarkers and targeted therapies. <i>Nature Reviews Neurology</i> , 2018, 14, 22-39.	10.1	303

#	ARTICLE	IF	CITATIONS
37	Multimodal analysis of aged wild-type mice exposed to repeated scanning ultrasound treatments demonstrates long-term safety. <i>Theranostics</i> , 2018, 8, 6233-6247.	10.0	30
38	Are you <i><scp>TORC</scp>ing tau </i> me? Amyloid β^2 blocks the conversation between lysosomes and mitochondria. <i>EMBO Journal</i> , 2018, 37, .	7.8	4
39	Rodent models for Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2018, 19, 583-598.	10.2	240
40	Local Oxidative Damage in the Soma and Dendrites Quarantines Neuronal Mitochondria at the Site of Insult. <i>IScience</i> , 2018, 6, 114-127.	4.1	19
41	Pyk2 is a Novel Tau Tyrosine Kinase that \hat{A} is \hat{A} Regulated by the Tyrosine Kinase Fyn. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 205-221.	2.6	36
42	Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice. <i>Frontiers in Neuroscience</i> , 2018, 12, 55.	2.8	50
43	Exosomes taken up by neurons hijack the endosomal pathway to spread to interconnected neurons. <i>Acta Neuropathologica Communications</i> , 2018, 6, 10.	5.2	127
44	Establishing sheep as an experimental species to validate ultrasound-mediated blood-brain barrier opening for potential therapeutic interventions. <i>Theranostics</i> , 2018, 8, 2583-2602.	10.0	35
45	Modeling ultrasound propagation through material of increasing geometrical complexity. <i>Ultrasonics</i> , 2018, 90, 52-62.	3.9	7
46	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	6.1	23
47	Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. <i>Acta Neuropathologica</i> , 2017, 133, 717-730.	7.7	108
48	Accelerated aging exacerbates a pre \hat{e} existing pathology in a tau transgenic mouse model. <i>Aging Cell</i> , 2017, 16, 377-386.	6.7	29
49	The amyloid β^2 oligomer $A\hat{1}^2*56$ induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. <i>Science Signaling</i> , 2017, 10, .	3.6	90
50	Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. <i>Brain</i> , 2017, 140, 1220-1230.	7.6	158
51	Off-loading strategies in diabetic foot syndrome \hat{e} evaluation of different devices. <i>International Orthopaedics</i> , 2017, 41, 239-246.	1.9	19
52	Tau-based therapies in neurodegeneration: opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 863-883.	46.4	193
53	Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn \hat{e} mediated local protein translation. <i>EMBO Journal</i> , 2017, 36, 3120-3138.	7.8	140
54	Ultrasound as a treatment modality for neurological diseases. <i>Medical Journal of Australia</i> , 2017, 206, 470-471.	1.7	1

#	ARTICLE	IF	CITATIONS
55	A corticostriatal deficit promotes temporal distortion of automatic action in ageing. <i>ELife</i> , 2017, 6, .	6.0	12
56	Scanning Ultrasound (SUS) Causes No Changes to Neuronal Excitability and Prevents Age-Related Reductions in Hippocampal CA1 Dendritic Structure in Wild-Type Mice. <i>PLoS ONE</i> , 2016, 11, e0164278.	2.5	26
57	Glutamate Receptors in Alzheimerâ€™s Disease: Mechanisms and Therapies. <i>Neural Plasticity</i> , 2016, 2016, 1-2.	2.2	14
58	Quantitative Imaging of Cholinergic Interneurons Reveals a Distinctive Spatial Organization and a Functional Gradient across the Mouse Striatum. <i>PLoS ONE</i> , 2016, 11, e0157682.	2.5	35
59	Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1207-1217.	2.6	69
60	Mobility and subcellular localization of endogenous, gene-edited Tau differs from that of over-expressed human wild-type and P301L mutant Tau. <i>Scientific Reports</i> , 2016, 6, 29074.	3.3	37
61	Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner. <i>Journal of Biological Chemistry</i> , 2016, 291, 12445-12466.	3.4	208
62	A local insult of okadaic acid in wild-type mice induces tau phosphorylation and protein aggregation in anatomically distinct brain regions. <i>Acta Neuropathologica Communications</i> , 2016, 4, 32.	5.2	31
63	Aging-Related Dysfunction of Striatal Cholinergic Interneurons Produces Conflict in Action Selection. <i>Neuron</i> , 2016, 90, 362-373.	8.1	74
64	Munc18-1 is a molecular chaperone for α -synuclein, controlling its self-replicating aggregation. <i>Journal of Cell Biology</i> , 2016, 214, 705-718.	5.2	56
65	Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimerâ€™s disease. <i>Translational Psychiatry</i> , 2016, 6, e907-e907.	4.8	194
66	Tau physiology and pathomechanisms in frontotemporal lobar degeneration. <i>Journal of Neurochemistry</i> , 2016, 138, 71-94.	3.9	85
67	Special issue on â€˜Cytoskeletal proteins in health and neurodegenerative diseaseâ€™. <i>Brain Research Bulletin</i> , 2016, 126, 213-216.	3.0	6
68	Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.	1.1	76
69	Ultrasound treatment of neurological diseases â€” current and emerging applications. <i>Nature Reviews Neurology</i> , 2016, 12, 161-174.	10.1	200
70	Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. <i>Neurobiology of Learning and Memory</i> , 2016, 130, 34-43.	1.9	24
71	Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease. <i>Journal of Biological Chemistry</i> , 2016, 291, 8173-8188.	3.4	117
72	The frontotemporal dementia-motor neuron disease continuum. <i>Lancet, The</i> , 2016, 388, 919-931.	13.7	294

#	ARTICLE	IF	CITATIONS
73	Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid- β^2 or hyperphosphorylated tau protein. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 201-215.	5.4	79
74	No full admission for tau to the exclusive prion club yet. <i>EMBO Journal</i> , 2015, 34, 2990-2992.	7.8	9
75	Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 913-924.	3.8	81
76	Tau- ϵ -targeting passive immunization modulates aspects of pathology in tau transgenic mice. <i>Journal of Neurochemistry</i> , 2015, 132, 135-145.	3.9	70
77	Scanning ultrasound removes amyloid- β^2 and restores memory in an Alzheimer's disease mouse model. <i>Science Translational Medicine</i> , 2015, 7, 278ra33.	12.4	409
78	What we can learn from animal models about cerebral multi-morbidity. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 11.	6.2	8
79	FTD and ALS- ϵ -translating mouse studies into clinical trials. <i>Nature Reviews Neurology</i> , 2015, 11, 360-366.	10.1	64
80	Neuronal protein with tau-like repeats (PTL-1) regulates intestinal SKN-1 nuclear accumulation in response to oxidative stress. <i>Aging Cell</i> , 2015, 14, 148-151.	6.7	10
81	Tau aggregation and its interplay with amyloid- β^2 . <i>Acta Neuropathologica</i> , 2015, 129, 207-220.	7.7	283
82	Connecting the dots between tau dysfunction and neurodegeneration. <i>Trends in Cell Biology</i> , 2015, 25, 46-53.	7.9	108
83	Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 40.	2.9	21
84	Altered proteostasis in aging and heat shock response in <i>C. elegans</i> revealed by analysis of the global and de novo synthesized proteome. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 3339-3361.	5.4	63
85	Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and $A\beta^2$ amyloidosis. <i>Neurobiology of Disease</i> , 2014, 71, 169-179.	4.4	45
86	Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in <i>Caenorhabditis elegans</i> . <i>Nature Protocols</i> , 2014, 9, 2237-2255.	12.0	39
87	Visualizing the microtubule-associated protein tau in the nucleus. <i>Science China Life Sciences</i> , 2014, 57, 422-431.	4.9	36
88	The herbal compound geniposide rescues formaldehyde-induced apoptosis in N2a neuroblastoma cells. <i>Science China Life Sciences</i> , 2014, 57, 412-421.	4.9	26
89	March separate, strike together - Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1258-1266.	3.8	92
90	Regulation of age-related structural integrity in neurons by protein with tau-like repeats (PTL-1) is cell autonomous. <i>Scientific Reports</i> , 2014, 4, 5185.	3.3	12

#	ARTICLE	IF	CITATIONS
91	Single Nucleotide Variants (SNVs) Define Senescence-Accelerated SAMP8 Mice, a Model of a Geriatric Condition. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 349-363.	2.6	7
92	Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice. <i>Neurobiology of Aging</i> , 2013, 34, 1369-1379.	3.1	40
93	Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice. <i>Brain Research</i> , 2013, 1497, 73-84.	2.2	10
94	Glutamate Metabolism is Impaired in Transgenic Mice with Tau Hyperphosphorylation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 684-691.	4.3	54
95	Why size matters – balancing mitochondrial dynamics in Alzheimer's disease. <i>Trends in Neurosciences</i> , 2013, 36, 325-335.	8.6	150
96	How it all Started: Tau and Protein Phosphatase 2A. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 483-494.	2.6	24
97	Protein with tau-like repeats regulates neuronal integrity and lifespan in <i>C. elegans</i> . <i>Journal of Cell Science</i> , 2013, 126, 2079-91.	2.0	49
98	Ageing in the nervous system of <i>Caenorhabditis elegans</i> . <i>Communicative and Integrative Biology</i> , 2013, 6, e25288.	1.4	8
99	Profiling Murine Tau with ON, 1N and 2N Isoform-Specific Antibodies in Brain and Peripheral Organs Reveals Distinct Subcellular Localization, with the 1N Isoform Being Enriched in the Nucleus. <i>PLoS ONE</i> , 2013, 8, e84849.	2.5	123
100	Lessons from two prevalent amyloidoses – what amylin and A β have in common. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 38.	3.4	36
101	What Renders TAU Toxic. <i>Frontiers in Neurology</i> , 2013, 4, 72.	2.4	67
102	Alzheimer's disease models and functional genomics – How many needles are there in the haystack?. <i>Frontiers in Physiology</i> , 2012, 3, 320.	2.8	18
103	A neuroprotective role for the DNA damage checkpoint in tauopathy. <i>Aging Cell</i> , 2012, 11, 360-362.	6.7	47
104	Decoding the non-coding RNAs in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 3543-3559.	5.4	60
105	Role of hippocampin in mediating A β toxicity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1247-1257.	3.8	12
106	Insights into Mitochondrial Dysfunction: Aging, Amyloid- β , and Tau – A Deleterious Trio. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1456-1466.	5.4	115
107	Tau Promotes Neurodegeneration via DRP1 Mislocalization In Vivo. <i>Neuron</i> , 2012, 75, 618-632.	8.1	331
108	Alzheimer's Disease, Oestrogen and Mitochondria: an Ambiguous Relationship. <i>Molecular Neurobiology</i> , 2012, 46, 151-160.	4.0	51

#	ARTICLE	IF	CITATIONS
109	Tau-targeted treatment strategies in Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2012, 165, 1246-1259.	5.4	114
110	MicroRNA networks surrounding APP and amyloid- β metabolism – Implications for Alzheimer's disease. <i>Experimental Neurology</i> , 2012, 235, 447-454.	4.1	90
111	Target Gene Repression Mediated by miRNAs miR-181c and miR-9 Both of Which Are Down-regulated by Amyloid- β . <i>Journal of Molecular Neuroscience</i> , 2012, 46, 324-335.	2.3	139
112	Tau-Mediated Nuclear Depletion and Cytoplasmic Accumulation of SFPQ in Alzheimer's and Pick's Disease. <i>PLoS ONE</i> , 2012, 7, e35678.	2.5	82
113	Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid- β toxicity. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 15.	6.2	136
114	Novel functions of the protein tau in disease. <i>Neuroscience Research</i> , 2011, 71, e26.	1.9	0
115	Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation. <i>Neurobiology of Aging</i> , 2011, 32, 991-1006.	3.1	24
116	Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. <i>PLoS ONE</i> , 2011, 6, e26860.	2.5	142
117	Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid- β -Mediated Deregulation of Estradiol. <i>PLoS ONE</i> , 2011, 6, e28887.	2.5	49
118	Amyloid- β and tau – a toxic pas de deux in Alzheimer's disease. <i>Nature Reviews Neuroscience</i> , 2011, 12, 67-72.	10.2	1,147
119	Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice. <i>Journal of Neural Transmission</i> , 2011, 118, 737-745.	2.8	19
120	Modes of A β toxicity in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3359-3375.	5.4	78
121	Brief update on different roles of tau in neurodegeneration. <i>IUBMB Life</i> , 2011, 63, 495-502.	3.4	42
122	Mice lacking phosphatase PP2A subunit PR61/B α (<i>Ppp2r5d</i>) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3 β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6957-6962.	7.1	105
123	ENU Mutagenesis Screen to Establish Motor Phenotypes in Wild-Type Mice and Modifiers of a Pre-Existing Motor Phenotype in Tau Mutant Mice. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 1-11.	3.0	8
124	Chapter 5. Invertebrate and Vertebrate Models of Tauopathies. <i>RSC Drug Discovery Series</i> , 2011, , 69-85.	0.3	1
125	Cytoplasmic Accumulation and Aggregation of TDP-43 upon Proteasome Inhibition in Cultured Neurons. <i>PLoS ONE</i> , 2011, 6, e22850.	2.5	91
126	Convergence of Amyloid- β and Tau Pathologies on Mitochondria In Vivo. <i>Molecular Neurobiology</i> , 2010, 41, 107-114.	4.0	144

#	ARTICLE	IF	CITATIONS
127	Gateway-compatible lentiviral transfer vectors for ubiquitin promoter driven expression of fluorescent fusion proteins. <i>Plasmid</i> , 2010, 63, 155-160.	1.4	11
128	Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. <i>Brain Research</i> , 2010, 1347, 111-124.	2.2	8
129	A β and human amylin share a common toxicity pathway <i>via</i> mitochondrial dysfunction. <i>Proteomics</i> , 2010, 10, 1621-1633.	2.2	112
130	Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid- β . <i>PLoS ONE</i> , 2010, 5, e11070.	2.5	183
131	Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13888-13893.	7.1	237
132	Dissecting Toxicity of Tau and β -Amyloid. <i>Neurodegenerative Diseases</i> , 2010, 7, 10-12.	1.4	25
133	Animal models reveal role for tau phosphorylation in human disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 860-871.	3.8	67
134	Dendritic Function of Tau Mediates Amyloid- β Toxicity in Alzheimer's Disease Mouse Models. <i>Cell</i> , 2010, 142, 387-397.	28.9	1,563
135	Parkinson's disease: Insights from non-traditional model organisms. <i>Progress in Neurobiology</i> , 2010, 92, 558-571.	5.7	60
136	Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2009, 4, e7917.	2.5	161
137	Amyloid- β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20057-20062.	7.1	581
138	Animal Models for Alzheimer's Disease and Frontotemporal Dementia: A Perspective. <i>ASN Neuro</i> , 2009, 1, AN20090042.	2.7	31
139	Phosphorylated Tau Interacts with c-Jun N-terminal Kinase-interacting Protein 1 (JIP1) in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2009, 284, 20909-20916.	3.4	139
140	Phosphorylation of soluble tau differs in Pickâ€™s disease and Alzheimerâ€™s disease brains. <i>Journal of Neural Transmission</i> , 2009, 116, 1243-1251.	2.8	35
141	Response to the comment â€˜Iron, type 2 diabetes mellitus, and Alzheimerâ€™s diseaseâ€™ to our Visions and Reflections article â€˜Common features between diabetes mellitus and Alzheimerâ€™s diseaseâ€™. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 2945-2945.	5.4	0
142	Common features between diabetes mellitus and Alzheimerâ€™s disease. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 1321-1325.	5.4	100
143	Primary support cultures of hippocampal and substantia nigra neurons. <i>Nature Protocols</i> , 2009, 4, 78-85.	12.0	185
144	Workshop 4. <i>Journal of Neurochemistry</i> , 2009, 110, 59-60.	3.9	0

#	ARTICLE	IF	CITATIONS
145	Substrate-specific reduction of PP2A activity exaggerates tau pathology. <i>Biochemical and Biophysical Research Communications</i> , 2009, 379, 400-405.	2.1	36
146	Alzheimer's Disease Selective Vulnerability and Modeling in Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 243-251.	2.6	29
147	Oligomeric and fibrillar species of β -amyloid ($A\beta_{42}$) both impair mitochondrial function in P301L tau transgenic mice. <i>Journal of Molecular Medicine</i> , 2008, 86, 1255-1267.	3.9	123
148	Neuroproteomics as a promising tool in Parkinson's disease research. <i>Journal of Neural Transmission</i> , 2008, 115, 1413-1430.	2.8	26
149	Animal models of Alzheimer's disease and frontotemporal dementia. <i>Nature Reviews Neuroscience</i> , 2008, 9, 532-544.	10.2	604
150	Divergent phosphorylation pattern of tau in P301L tau transgenic mice. <i>European Journal of Neuroscience</i> , 2008, 28, 137-147.	2.6	76
151	Human but not rat amylin shares neurotoxic properties with $A\beta_{42}$ in long-term hippocampal and cortical cultures. <i>FEBS Letters</i> , 2008, 582, 2188-2194.	2.8	64
152	Antiviral CD8 T Cells Recognize Borna Disease Virus Antigen Transgenically Expressed in either Neurons or Astrocytes. <i>Journal of Virology</i> , 2008, 82, 3099-3108.	3.4	13
153	Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15997-16002.	7.1	201
154	Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice. <i>Neurodegenerative Diseases</i> , 2008, 5, 157-159.	1.4	134
155	Functional Genomics Dissects Pathomechanisms in Tauopathies: Mitosis Failure and Unfolded Protein Response. <i>Neurodegenerative Diseases</i> , 2008, 5, 179-181.	1.4	9
156	Transgenic mice with ocular overexpression of an adrenomedullin receptor reflect human acute angle-closure glaucoma. <i>Clinical Science</i> , 2008, 114, 49-58.	4.3	18
157	Is Tau Aggregation Toxic or Protective: A Sensible Question in the Absence of Sensitive Methods?. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 423-429.	2.6	31
158	An update on the toxicity of $A\beta$ in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1033.	2.2	32
159	Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing $A\beta$ protofibrils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19232-19237.	7.1	204
160	Possibilities for the prevention and treatment of cognitive impairment and dementia. <i>British Journal of Psychiatry</i> , 2007, 190, 371-372.	2.8	20
161	Pronuclear injection for the production of transgenic mice. <i>Nature Protocols</i> , 2007, 2, 1206-1215.	12.0	159
162	A Decade of Tau Transgenic Animal Models and Beyond. <i>Brain Pathology</i> , 2007, 17, 91-103.	4.1	145

#	ARTICLE	IF	CITATIONS
163	A β treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry. <i>European Journal of Neuroscience</i> , 2007, 26, 60-72.	2.6	31
164	Impact of β -Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models. , 2007, , 198-215.		0
165	Impaired development of the Harderian gland in mutant protein phosphatase 2A transgenic mice. <i>Mechanisms of Development</i> , 2006, 123, 362-371.	1.7	15
166	P70 S6 kinase mediates tau phosphorylation and synthesis. <i>FEBS Letters</i> , 2006, 580, 107-114.	2.8	105
167	Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice. <i>Biochemical and Biophysical Research Communications</i> , 2006, 343, 1171-1178.	2.1	37
168	Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation. <i>International Journal of Developmental Neuroscience</i> , 2006, 24, 437-443.	1.6	15
169	Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?. <i>Medical Journal of Australia</i> , 2006, 185, 381-384.	1.7	27
170	β -Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. <i>Proteomics</i> , 2006, 6, 6566-6577.	2.2	62
171	Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?. <i>Journal of Neurochemistry</i> , 2006, 98, 993-1006.	3.9	113
172	Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. <i>Genes, Brain and Behavior</i> , 2006, 5, 369-379.	2.2	94
173	Active immunization trial in A β 42-injected P301L tau transgenic mice. <i>Neurobiology of Disease</i> , 2006, 22, 50-56.	4.4	18
174	Enhanced Vascular Responses to Adrenomedullin in Mice Overexpressing Receptor-Activity-Modifying Protein 2. <i>Circulation Research</i> , 2006, 98, 262-270.	4.5	50
175	Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2005, 280, 23802-23814.	3.4	362
176	Different tau epitopes define A β 42-mediated tau insolubility. <i>Biochemical and Biophysical Research Communications</i> , 2005, 337, 1097-1101.	2.1	34
177	Functional Genomics meets neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2005, 76, 153-168.	5.7	33
178	Functional Genomics meets neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2005, 76, 169-188.	5.7	42
179	Role of the protein tau in Alzheimer's disease. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 395-400.	0.8	1
180	Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals. <i>Current Drug Targets</i> , 2004, 5, 503-515.	2.1	99

#	ARTICLE	IF	CITATIONS
181	Transgenic Mice Expressing the Nucleoprotein of Borna Disease Virus in either Neurons or Astrocytes: Decreased Susceptibility to Homotypic Infection and Disease. <i>Journal of Virology</i> , 2004, 78, 3621-3632.	3.4	22
182	Role for glyoxalase I in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 7687-7692.	7.1	150
183	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. <i>Molecular Psychiatry</i> , 2004, 9, 664-683.	7.9	248
184	Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. <i>Analytical Biochemistry</i> , 2004, 335, 30-41.	2.4	73
185	Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. <i>Neurobiology of Disease</i> , 2004, 15, 500-509.	4.4	81
186	Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue culture models. <i>International Journal of Developmental Neuroscience</i> , 2004, 22, 453-465.	1.6	122
187	Genomic Organisation, Chromosomal Localisation Tissue Distribution and Developmental Regulation of the PR61/B Regulatory Subunits of Protein Phosphatase 2A in Mice. <i>Journal of Molecular Biology</i> , 2004, 336, 971-986.	4.2	53
188	Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. <i>EMBO Journal</i> , 2003, 22, 3095-3101.	7.8	66
189	Activation of the ERK and JNK Signaling Pathways Caused by Neuron-Specific Inhibition of PP2A in Transgenic Mice. <i>American Journal of Pathology</i> , 2003, 163, 833-843.	3.8	147
190	Î²-Amyloid Induces Paired Helical Filament-like Tau Filaments in Tissue Culture. <i>Journal of Biological Chemistry</i> , 2003, 278, 40162-40168.	3.4	159
191	Saitohin gene is not associated with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 362-363.	1.9	19
192	Transgenic and Knockout Models of PP2A. <i>Methods in Enzymology</i> , 2003, 366, 390-403.	1.0	27
193	Glial Cells Under Physiologic and Pathologic Conditions. <i>Archives of Neurology</i> , 2002, 59, 1524.	4.5	77
194	Alzheimer's and Parkinson's disease " overlapping or synergistic pathologies?. <i>Trends in Molecular Medicine</i> , 2002, 8, 3-5.	6.7	57
195	Diversity, developmental regulation and distribution of murine PR55/B subunits of protein phosphatase 2A. <i>European Journal of Neuroscience</i> , 2002, 16, 2039-2048.	2.6	50
196	Interactions of Beta-Amyloid with the Formation of Neurofibrillary Tangles in Transgenic Mice. <i>Advances in Behavioral Biology</i> , 2002, , 139-144.	0.2	0
197	Tau and transgenic animal models. <i>Brain Research Reviews</i> , 2001, 35, 266-286.	9.0	142
198	Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. <i>European Journal of Neuroscience</i> , 2001, 13, 2131-2140.	2.6	96

#	ARTICLE	IF	CITATIONS
199	Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by A ^Δ 242 Fibrils. <i>Science</i> , 2001, 293, 1491-1495.	12.6	1,410
200	Tau Filament Formation in Transgenic Mice Expressing P301L Tau. <i>Journal of Biological Chemistry</i> , 2001, 276, 529-534.	3.4	433
201	Reduced Protein Phosphatase 2A Activity Induces Hyperphosphorylation and Altered Compartmentalization of Tau in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2001, 276, 38193-38200.	3.4	184
202	Human Tau Transgenic Mice. <i>Advances in Experimental Medicine and Biology</i> , 2001, , 71-83.	1.6	7
203	Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. <i>Acta Neuropathologica</i> , 2000, 99, 469-481.	7.7	344
204	Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types. <i>FEBS Letters</i> , 2000, 486, 121-125.	2.8	43
205	Distinct role of protein phosphatase 2A subunit C ^Δ in the regulation of E-cadherin and β -catenin during development. <i>Mechanisms of Development</i> , 2000, 93, 83-93.	1.7	81
206	The Role of Protein Phosphatase 2A Catalytic Subunit C ^Δ in Embryogenesis: Evidence from Sequence Analysis and Localization Studies. <i>Biological Chemistry</i> , 1999, 380, 1117-1120.	2.5	13
207	Expression of Amino-Terminally Truncated PrP in the Mouse Leading to Ataxia and Specific Cerebellar Lesions. <i>Cell</i> , 1998, 93, 203-214.	28.9	506
208	Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit C ^Δ . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 12370-12375.	7.1	195
209	Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 6158-6162.	7.1	139
210	FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations. <i>Cell</i> , 1994, 78, 1017-1025.	28.9	551
211	Non-tolerance and differential susceptibility to diabetes in transgenic mice expressing major histocompatibility class II genes on pancreatic β cells. <i>European Journal of Immunology</i> , 1990, 20, 1677-1683.	2.9	22